Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 1
1982 2
1983 3
1984 1
1985 2
1986 1
1987 7
1988 5
1989 5
1990 8
1991 15
1992 15
1993 20
1994 23
1995 28
1996 33
1997 28
1998 32
1999 32
2000 45
2001 35
2002 40
2003 52
2004 48
2005 46
2006 45
2007 75
2008 93
2009 85
2010 74
2011 108
2012 112
2013 136
2014 141
2015 136
2016 144
2017 98
2018 118
2019 141
2020 145
2021 157
2022 118
2023 81
2024 46

Text availability

Article attribute

Article type

Publication date

Search Results

2,192 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Grade 4 Clear Cell Renal Cell Carcinoma"
Page 1
Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial.
Motzer RJ, Powles T, Burotto M, Escudier B, Bourlon MT, Shah AY, Suárez C, Hamzaj A, Porta C, Hocking CM, Kessler ER, Gurney H, Tomita Y, Bedke J, Zhang J, Simsek B, Scheffold C, Apolo AB, Choueiri TK. Motzer RJ, et al. Lancet Oncol. 2022 Jul;23(7):888-898. doi: 10.1016/S1470-2045(22)00290-X. Epub 2022 Jun 7. Lancet Oncol. 2022. PMID: 35688173 Free PMC article. Clinical Trial.
BACKGROUND: In the primary analysis of CheckMate 9ER, nivolumab plus cabozantinib showed superior progression-free survival, overall survival, and objective response over sunitinib in patients with previously untreated advanced renal cell carcinoma (median fo …
BACKGROUND: In the primary analysis of CheckMate 9ER, nivolumab plus cabozantinib showed superior progression-free survival, overall surviva …
Grading of renal cell carcinoma.
Delahunt B, Eble JN, Egevad L, Samaratunga H. Delahunt B, et al. Histopathology. 2019 Jan;74(1):4-17. doi: 10.1111/his.13735. Histopathology. 2019. PMID: 30565310 Review.
Grading of renal cell carcinoma (RCC) has been recognised as a prognostic factor for almost 100 years. ...This grading system has been validated for both clear cell and papillary RCC. ...
Grading of renal cell carcinoma (RCC) has been recognised as a prognostic factor for almost 100 years. .. …
Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Powles T, Tomczak P, Park SH, Venugopal B, Ferguson T, Symeonides SN, Hajek J, Gurney H, Chang YH, Lee JL, Sarwar N, Thiery-Vuillemin A, Gross-Goupil M, Mahave M, Haas NB, Sawrycki P, Burgents JE, Xu L, Imai K, Quinn DI, Choueiri TK; KEYNOTE-564 Investigators. Powles T, et al. Lancet Oncol. 2022 Sep;23(9):1133-1144. doi: 10.1016/S1470-2045(22)00487-9. Lancet Oncol. 2022. PMID: 36055304 Free article. Clinical Trial.
BACKGROUND: The first interim analysis of the KEYNOTE-564 study showed improved disease-free survival with adjuvant pembrolizumab compared with placebo after surgery in patients with clear cell renal cell carcinoma at an increased risk of recurr …
BACKGROUND: The first interim analysis of the KEYNOTE-564 study showed improved disease-free survival with adjuvant pembrolizumab compared w …
Management of Renal Masses and Localized Renal Cancer: Systematic Review and Meta-Analysis.
Pierorazio PM, Johnson MH, Patel HD, Sozio SM, Sharma R, Iyoha E, Bass EB, Allaf ME. Pierorazio PM, et al. J Urol. 2016 Oct;196(4):989-99. doi: 10.1016/j.juro.2016.04.081. Epub 2016 May 6. J Urol. 2016. PMID: 27157369 Free PMC article. Review.
We summarize evidence on effectiveness and comparative effectiveness of these treatment approaches for patients with a renal mass suspicious for localized renal cell carcinoma. MATERIALS AND METHODS: We searched MEDLINE, Embase and the Cochrane Central …
We summarize evidence on effectiveness and comparative effectiveness of these treatment approaches for patients with a renal mass sus …
The International Society of Urological Pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters.
Delahunt B, Cheville JC, Martignoni G, Humphrey PA, Magi-Galluzzi C, McKenney J, Egevad L, Algaba F, Moch H, Grignon DJ, Montironi R, Srigley JR; Members of the ISUP Renal Tumor Panel. Delahunt B, et al. Am J Surg Pathol. 2013 Oct;37(10):1490-504. doi: 10.1097/PAS.0b013e318299f0fb. Am J Surg Pathol. 2013. PMID: 24025520
There was consensus that the main morphotypes of renal cell carcinoma (RCC) were of prognostic significance, that subtyping of papillary RCC (types 1 and 2) provided additional prognostic information, and that clear cell tubulopapi …
There was consensus that the main morphotypes of renal cell carcinoma (RCC) were of prognostic significance, tha …
Circular RNA circ-TNPO3 inhibits clear cell renal cell carcinoma metastasis by binding to IGF2BP2 and destabilizing SERPINH1 mRNA.
Pan X, Huang B, Ma Q, Ren J, Liu Y, Wang C, Zhang D, Fu J, Ran L, Yu T, Li H, Wang X, Yang F, Liang C, Zhang Y, Wang S, Ren J, Li W, Wang Y, Xiao B. Pan X, et al. Clin Transl Med. 2022 Jul;12(7):e994. doi: 10.1002/ctm2.994. Clin Transl Med. 2022. PMID: 35876041 Free PMC article.
BACKGROUND: Clear cell renal cell carcinoma (ccRCC) is a common malignant tumour of the urinary tract. ...However, the role of circRNAs in ccRCC is still uncertain. METHODS: The circRNAs microarray (n = 4) was performed to investigate the …
BACKGROUND: Clear cell renal cell carcinoma (ccRCC) is a common malignant tumour of the urinary tract. .. …
Multimodal recurrence scoring system for prediction of clear cell renal cell carcinoma outcome: a discovery and validation study.
Gui CP, Chen YH, Zhao HW, Cao JZ, Liu TJ, Xiong SW, Yu YF, Liao B, Cao Y, Li JY, Huang KB, Han H, Zhang ZL, Chen WF, Jiang ZY, Gao Y, Han GP, Tang Q, Ouyang K, Qu GM, Wu JT, Guo JP, Li CX, Li PX, Liu ZP, Hsieh JT, Cai MY, Li XS, Wei JH, Luo JH. Gui CP, et al. Lancet Digit Health. 2023 Aug;5(8):e515-e524. doi: 10.1016/S2589-7500(23)00095-X. Epub 2023 Jun 29. Lancet Digit Health. 2023. PMID: 37393162 Free article.
BACKGROUND: Improved markers for predicting recurrence are needed to stratify patients with localised (stage I-III) renal cell carcinoma after surgery for selection of adjuvant therapy. ...INTERPRETATION: Our multimodal recurrence score is a practical …
BACKGROUND: Improved markers for predicting recurrence are needed to stratify patients with localised (stage I-III) renal c …
Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial.
Choueiri TK, Escudier B, Powles T, Tannir NM, Mainwaring PN, Rini BI, Hammers HJ, Donskov F, Roth BJ, Peltola K, Lee JL, Heng DYC, Schmidinger M, Agarwal N, Sternberg CN, McDermott DF, Aftab DT, Hessel C, Scheffold C, Schwab G, Hutson TE, Pal S, Motzer RJ; METEOR investigators. Choueiri TK, et al. Lancet Oncol. 2016 Jul;17(7):917-927. doi: 10.1016/S1470-2045(16)30107-3. Epub 2016 Jun 5. Lancet Oncol. 2016. PMID: 27279544 Clinical Trial.
The randomised phase 3 METEOR trial compared the efficacy and safety of cabozantinib versus the mTOR inhibitor everolimus in patients with advanced renal cell carcinoma who progressed after previous VEGFR tyrosine-kinase inhibitor treatment. ...METHODS: In th …
The randomised phase 3 METEOR trial compared the efficacy and safety of cabozantinib versus the mTOR inhibitor everolimus in patients with a …
Machine learning-based pathomics signature could act as a novel prognostic marker for patients with clear cell renal cell carcinoma.
Chen S, Jiang L, Gao F, Zhang E, Wang T, Zhang N, Wang X, Zheng J. Chen S, et al. Br J Cancer. 2022 Mar;126(5):771-777. doi: 10.1038/s41416-021-01640-2. Epub 2021 Nov 25. Br J Cancer. 2022. PMID: 34824449 Free PMC article.
BACKGROUND: Traditional histopathology performed by pathologists through naked eyes is insufficient for accurate survival prediction of clear cell renal cell carcinoma (ccRCC). METHODS: A total of 483 whole slide images (WSIs) data from t …
BACKGROUND: Traditional histopathology performed by pathologists through naked eyes is insufficient for accurate survival prediction …
Immune classification of clear cell renal cell carcinoma.
Su S, Akbarinejad S, Shahriyari L. Su S, et al. Sci Rep. 2021 Feb 22;11(1):4338. doi: 10.1038/s41598-021-83767-z. Sci Rep. 2021. PMID: 33619294 Free PMC article.
Since the outcome of treatments, particularly immunotherapeutic interventions, depends on the tumor immune micro-environment (TIM), several experimental and computational tools such as flow cytometry, immunohistochemistry, and digital cytometry have been developed and utilized to …
Since the outcome of treatments, particularly immunotherapeutic interventions, depends on the tumor immune micro-environment (TIM), several …
2,192 results